About Tellus Therapeutics
Tellus Therapeutics is a company based in Durham (United States) founded in 2018 by Eric Benner and Jason Kralic.. Tellus Therapeutics has raised $37 million across 5 funding rounds from investors including HHS, Xontogeny and NCBiotech. Tellus Therapeutics offers products and services including TT-20. Tellus Therapeutics operates in a competitive market with competitors including Sio Gene Therapies and Xenacoronus Healthcare, among others.
- Headquarter Durham, United States
- Founders Eric Benner, Jason Kralic
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$37 M (USD)
in 5 rounds
-
Latest Funding Round
$35 M (USD), Series A
Dec 13, 2022
-
Investors
HHS
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tellus Therapeutics
Tellus Therapeutics offers a comprehensive portfolio of products and services, including TT-20. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug aimed at preventing white matter injury in preterm infants
Unlock access to complete
Unlock access to complete
Funding Insights of Tellus Therapeutics
Tellus Therapeutics has successfully raised a total of $37M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $35 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $35.0M
-
First Round
First Round
(24 Oct 2019)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2022 | Amount | Series A - Tellus Therapeutics | Valuation | Xontogeny |
|
| May, 2021 | Amount | Seed - Tellus Therapeutics | Valuation | Xontogeny |
|
| Sep, 2020 | Amount | Grant - Tellus Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tellus Therapeutics
Tellus Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Xontogeny and NCBiotech. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science startups are accelerated through focused programs by Xontogeny.
|
Founded Year | Domain | Location | |
|
Biotech startups are incubated and funded in North Carolina.
|
Founded Year | Domain | Location | |
|
Early-stage entrepreneurs are accelerated through MassChallenge's program.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tellus Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Tellus Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tellus Therapeutics Comparisons
Competitors of Tellus Therapeutics
Tellus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sio Gene Therapies and Xenacoronus Healthcare, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene therapies for rare pediatric neurodegenerative diseases are developed.
|
|
| domain | founded_year | HQ Location |
Develops innovative drugs for treating cardiology, gynecology, and pediatric diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tellus Therapeutics
Frequently Asked Questions about Tellus Therapeutics
When was Tellus Therapeutics founded?
Tellus Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Tellus Therapeutics located?
Tellus Therapeutics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Is Tellus Therapeutics a funded company?
Tellus Therapeutics is a funded company, having raised a total of $37M across 5 funding rounds to date. The company's 1st funding round was a Grant of $696.59K, raised on Oct 24, 2019.
What does Tellus Therapeutics do?
Tellus Therapeutics was founded in 2018 and is based in Durham, United States. Focus is placed on the biotechnology sector, where therapeutic products derived from human maternal breast milk are developed to address brain injuries in children. Operations center on compounds like TT-20, which supports oligodendrocyte differentiation in postnatal neural stem cells to treat white matter brain injury.
Who are the top competitors of Tellus Therapeutics?
Tellus Therapeutics's top competitors include Sio Gene Therapies and Xenacoronus Healthcare.
What products or services does Tellus Therapeutics offer?
Tellus Therapeutics offers TT-20.
Who are Tellus Therapeutics's investors?
Tellus Therapeutics has 4 investors. Key investors include HHS, Xontogeny, NCBiotech, and MassChallenge.